when metformin and it’s parent herb galega officinalis titrated simply to tolerance has been the proven gold standard for centuries, losing on average 6% of weight (up to 20kg in 2yrs) and halving the incidence of new diabetes, while in diabetics it almost halves the death rate and most major chronic degenerative diseases of aging.
The for-profit Disease Industry and the researchers and Regulators they pay will never stop trying to promote the profitable new over the proven cheap old. So it’s up to consumers- the public- to seek out the evidence for themselves.
Fenfluramine / Phen-Fen/ Ponderax crashed a decade ago after lethal complications .
Orlistat (foul faecal problems) and sibutramine(hypertension, nausea/vomiting, palpitation, and sweating) have major potential adverse effects, and do not do as well as metformin for longterm reduction in all-cause mortality and major adverse outcomes.
now Anti-obesity drug use suspended 23 Oct 2008
The European Medicines Agency is recommending doctors do not prescribe the anti-obesity drug rimonabant, also known as Acomplia – it says the risk of serious psychiatric problems and even suicide are too high.
Why accept risky mediocre new drugs (sibutramine, orlistat) or risky bariatric surgery (40% complications in first 6 months) when only metformin simply adjusted to tolerance has been shown for decades to reduce all-cause mortality by at least 1/3 to 1/2, and even reduce cancer incidence.
Tesofensine seems similar to sibutramine in it’s potential to increase bloodpressure, dry mouth, nausea, constipation, hard stools, diarrhoea, and insomnia. But the longest trial so far seems to be only 24 weeks.